Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPA1 | O60313 | 1/20 | 0.80 |
| ▸ | EIF5B | O60841 | 1/20 | 0.80 |
| ▸ | MET | P08581 | 1/20 | 0.80 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.80 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 2/20 | 0.34 |
| ▸ | CCND1 | P24385 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395844 | 0.92 | OPA1 (0.73) | OPA1EIF5BMETHMOX2HTR2A | |
| SCHEMBL1720679 | 0.90 | OPA1 (0.71) | OPA1EIF5BMETHMOX2HTR6 | |
| SCHEMBL1395744 | 0.90 | OPA1 (0.71) | OPA1EIF5BMETHMOX2HTR6 | |
| SCHEMBL1395776 | 0.89 | OPA1 (0.75) | OPA1EIF5BMETHMOX2HTR6 | |
| Tivantinib SCHEMBL224883 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL14865187 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL1395795 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL45306 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL44902 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL44944 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | claimed |
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150328208-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. | 2014-07-17 | — | — | US | disclosed |
| US-8754078-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130150310-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2396003-B1 | A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib | ARQULE INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8377927-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2289892-B1 | Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer | ARQULE INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-1846406-B9 | MALEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE INC (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2289892-A1 | Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer | ArQule, Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20100297075-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| EP-1846406-B1 | MALEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE INC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100221251-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-7713969-B2 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20060223760-A1 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297075-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | TP53, MKI67, POLI | OPA1 218/4885EIF5B 490/4885MET 1267/4885 |
| US-20150328208-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | TP53, MKI67, POLI | OPA1 218/4885EIF5B 490/4885MET 1267/4885 |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | MKI67, NUP205, TP53 | OPA1 88/4885EIF5B 402/4885MET 2895/4885 |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | MKI67, NUP205, TP53 | OPA1 88/4885EIF5B 402/4885MET 2895/4885 |
| US-20100221251-A1 | Compositions and Methods for Treatment of Cancer | PDCD5, TP53, NUP205 | OPA1 27/4885EIF5B 341/4885MET 2940/4885 |
| US-20130150310-A1 | Compositions and Methods for Treatment of Cancer | MKI67, NUP205, TP53 | OPA1 88/4885EIF5B 402/4885MET 2895/4885 |
| US-20060223760-A1 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | MCL1, BRCA1, IDO1 | OPA1 29/4885EIF5B 1690/4885MET 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.